Lior Shaltiel

Chief Executive Officer at NUREXONE BIOLOGIC INC.

Net worth: 166 600 $ as of 2026-06-29

Health Technology

Consumer Services

Profile

Lior Shaltiel currently works at NurExone Biologic, Inc., as Chief Executive Officer & Director from 2022, NurExone Biologic Ltd., as Chief Executive Officer & Director from 2021, and The Hebrew University of Jerusalem, as Head-BioMed MBA Program from 2015.

Known holdings in public companies

Company	Date	Number of shares	Valuation	Valuation date
NUREXONE BIOLOGIC INC 0.46%	2025-11-26	425,000 ( 0.46% )	166 600 $	2026-06-29

Lior Shaltiel active positions

Companies	Position	Start
NUREXONE BIOLOGIC INC.	Chief Executive Officer	2021-03-31
NurExone Biologic Ltd. NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury	Chief Executive Officer	2021-03-31
The Hebrew University of Jerusalem The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University	Corporate Officer/Principal	2015-09-30

All active positions of Lior Shaltiel

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Lior Shaltiel's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	3
The Hebrew University of Jerusalem The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
NurExone Biologic Ltd. NurExone Biologic Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury	Health Technology
NurExone Biologic, Inc. NurExone Biologic, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company which develops an off the shelf, non-invasive and revolutionary treatment for the reduction in the harmful results of spinal cord injury	Health Technology